₩93,500.00

Last traded 2024-08-14 — delisted

KSC · Healthcare · Drug Manufacturers - Specialty & Generic

Revenue

$477.8B +22.9% ▲

5Y CAGR: +22.5%

Gross Profit

$122.0B +1.9% ▲

5Y CAGR: +14.3%

Operating Income

$37.2B +3.2% ▲

5Y CAGR: +20.4%

Net Income

$22.0B +3.3% ▲

5Y CAGR: +20.6%

EPS (Diluted)

$505.39 +3.4% ▲

5Y CAGR: +18.4%

EBITDA

$57.4B +5.8% ▲

5Y CAGR: +16.2%

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$233.6B	$398.7B	$386.0B	$388.8B	$477.8B
YoY Growth	+34.6%	+70.7%	-3.2%	+0.7%	+22.9%
Cost of Revenue	$160.4B	$279.5B	$273.3B	$269.1B	$355.8B
Gross Profit	$73.2B	$119.3B	$112.8B	$119.7B	$122.0B
Gross Margin	31.3%	29.9%	29.2%	30.8%	25.5%
R&D Expenses	$4.6B	$6.4B	$8.0B	$12.7B	$13.0B
SG&A Expenses	$20.3B	$34.2B	$34.5B	$35.2B	$31.9B
Operating Expenses	$49.5B	$71.5B	$74.6B	$83.6B	$84.8B
Operating Income	$23.6B	$47.8B	$38.2B	$36.1B	$37.2B
Operating Margin	10.1%	12.0%	9.9%	9.3%	7.8%
Interest Expense	$4.6B	$5.4B	$6.2B	$8.3B	$7.5B
Income Before Tax	$20.1B	$42.5B	$30.5B	$26.2B	$29.8B
Tax Expense	-$812M	$7.9B	$4.5B	$4.9B	$7.8B
Net Income	$20.9B	$34.6B	$26.0B	$21.3B	$22.0B
Net Margin	9.0%	8.7%	6.7%	5.5%	4.6%
EPS (Diluted)	$539.07	$872.38	$707.91	$488.57	$505.39
EBITDA	$38.2B	$64.3B	$54.1B	$54.2B	$57.4B
Shares Outstanding	39M	40M	37M	44M	43M

Line Item	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4
Revenue	$97.0B	$117.2B	$128.1B	$135.6B	$112.5B	$131.3B	$138.2B	$154.4B
Cost of Revenue	$73.0B	$87.5B	$94.0B	$101.2B	$79.1B	$90.5B	$95.6B	$107.4B
Gross Profit	$23.9B	$29.6B	$34.1B	$34.3B	$33.4B	$40.8B	$42.6B	$47.0B
Gross Margin	24.7%	25.3%	26.6%	25.3%	29.7%	31.1%	30.8%	30.4%
R&D Expenses	$3.0B	$0	$0	$4.5B	$3.1B	$0	$4.2B	$8.9B
SG&A Expenses	$20.2B	$20.2B	$7.4B	$9.8B	$22.6B	$25.3B	$9.9B	$12.7B
Operating Expenses	$20.2B	$20.2B	$20.5B	$23.9B	$22.6B	$25.3B	$26.5B	$33.3B
Operating Income	$3.7B	$9.4B	$13.6B	$10.5B	$10.7B	$15.5B	$16.1B	$13.7B
Operating Margin	3.8%	8.0%	10.7%	7.7%	9.5%	11.8%	11.7%	8.9%
Interest Expense	$1.9B	$1.8B	$1.9B	$1.9B	$1.8B	$1.1B	$1.6B	$1.6B
Income Before Tax	$2.0B	$7.6B	$12.1B	$8.1B	$9.5B	$14.6B	$15.1B	$10.5B
Tax Expense	$116M	$2.0B	$3.8B	$1.9B	$2.2B	$3.5B	$3.7B	$1.6B
Net Income	$1.9B	$5.6B	$8.3B	$6.2B	$7.3B	$11.1B	$11.5B	$8.9B
Net Margin	1.9%	4.8%	6.5%	4.6%	6.5%	8.4%	8.3%	5.8%
EPS (Diluted)	$43.81	$135.13	$190.48	$142.77	$168.45	$255.11	$258.82	$200.51
EBITDA	$9.0B	$14.4B	$19.1B	$14.8B	$38.7B	$40.8B	$22.4B	$17.8B
Shares Outstanding	41M	41M	43M	43M	43M	43M	44M	44M

068760.KS KSC